RxDoctor Payments Data

Sandra Lemmel, APRN

Family · Corydon, INNPI 1588096499

Payments from drug & device makers

$561in general payments, 2019–2025

Across 27 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$196
  • Lilly USA, LLC$95
  • Otsuka America Pharmaceutical, Inc.$82
  • GSK$47
  • AbbVie$45
  • Pfizer$28
  • plus $68 from 4 others

What the payments were for

  • Food & beverage$561100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$561 in reported general payments places this provider in the 55th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$23,714
Medicare patients
173
Services billed
364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin32$38,279
EliquisApixaban44$35,710
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$25,393
OzempicSemaglutide26$24,214
JanuviaSitagliptin Phosphate21$23,448
RexultiBrexpiprazole14$20,452
Breo ElliptaFluticasone/Vilanterol32$12,679
TrulicityDulaglutide12$11,132
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,454
Combivent RespimatIpratropium/Albuterol Sulfate12$5,482
Humalog Kwikpen U-100Insulin Lispro14$4,756
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,204
Potassium Chloride47$1,967
Albuterol Sulfate HfaAlbuterol Sulfate89$1,868
Ondansetron OdtOndansetron14$1,756

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$47$44,52686 claims
PfizerEliquis$28$35,71044 claims
Novo NordiskOzempic$16$24,21426 claims
MerckJanuvia$16$23,44821 claims
Otsuka America Pharmaceutical, Inc.Rexulti$82$20,45214 claims
Lilly USA, LLCTrulicity$95$11,13212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,392 family providers in Indiana.

Other family in Corydon

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →